Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 52Neoplasms 36Colorectal Neoplasms 33Prostatic Neoplasms 31Carcinoma, Non-Small-Cell Lung 31Lung Neoplasms 30Pancreatic Neoplasms 21Multiple Myeloma 16Recurrence 14Ovarian Neoplasms 14Uterine Cervical Neoplasms 12Leukemia, Myeloid, Acute 11Carcinoma, Hepatocellular 11Neoplasm Metastasis 10Head and Neck Neoplasms 10Brain Neoplasms 10Melanoma 9Stomach Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Rectal Neoplasms 8Advanced Solid Tumors 8Triple Negative Breast Neoplasms 7Small Cell Lung Carcinoma 7Glioblastoma 7Endometrial Neoplasms 7Carcinoma, Renal Cell 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Glioma 6Esophageal Neoplasms 6Colonic Neoplasms 6

Interventions

darolutamide 1Rifampin 1Itraconazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Refractory or Relapsed Solid Tumors × 30 days × Clear all
NCT07620041 2026-06-02

QLC5508 in Advanced Solid Tumors:: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction

Qilu Pharmaceutical Co., Ltd.

Phase 1 Not yet recruiting
48 enrolled
Other solid neoplasm

Refractory or Relapsed Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡